A detailed history of Northern Trust Corp transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 352,512 shares of IPSC stock, worth $370,137. This represents 0.0% of its overall portfolio holdings.

Number of Shares
352,512
Previous 211,326 66.81%
Holding current value
$370,137
Previous $538,000 11.9%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.44 - $3.29 $203,307 - $464,501
141,186 Added 66.81%
352,512 $602,000
Q2 2024

Aug 14, 2024

BUY
$2.46 - $4.05 $65,709 - $108,179
26,711 Added 14.47%
211,326 $538,000
Q1 2024

May 14, 2024

SELL
$3.19 - $5.32 $4,351 - $7,256
-1,364 Reduced 0.73%
184,615 $771,000
Q4 2023

Feb 13, 2024

SELL
$1.28 - $3.32 $1,555 - $4,033
-1,215 Reduced 0.65%
185,979 $617,000
Q3 2023

Nov 13, 2023

BUY
$2.0 - $3.23 $14,148 - $22,849
7,074 Added 3.93%
187,194 $374,000
Q2 2023

Aug 11, 2023

BUY
$2.91 - $3.53 $50,770 - $61,587
17,447 Added 10.73%
180,120 $569,000
Q1 2023

May 15, 2023

SELL
$3.4 - $5.11 $15,708 - $23,608
-4,620 Reduced 2.76%
162,673 $564,000
Q4 2022

Feb 13, 2023

BUY
$4.84 - $11.58 $18,285 - $43,749
3,778 Added 2.31%
167,293 $858,000
Q3 2022

Nov 14, 2022

BUY
$8.57 - $13.1 $116,329 - $177,819
13,574 Added 9.05%
163,515 $1.62 Million
Q2 2022

Aug 12, 2022

BUY
$7.96 - $12.43 $123,037 - $192,130
15,457 Added 11.49%
149,941 $1.26 Million
Q1 2022

May 13, 2022

BUY
$11.62 - $15.92 $363,903 - $498,566
31,317 Added 30.36%
134,484 $1.69 Million
Q4 2021

Feb 08, 2022

SELL
$13.93 - $23.62 $8,650 - $14,668
-621 Reduced 0.6%
103,167 $1.64 Million
Q3 2021

Nov 15, 2021

BUY
$20.8 - $31.93 $2.16 Million - $3.31 Million
103,788 New
103,788 $2.61 Million

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $61.8M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.